GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

Core Insights - GT Biopharma has initiated patient dosing in a Phase 1 trial for GTB-3650, targeting relapsed or refractory CD33 expressing hematologic malignancies, with initial data expected in 2025 [1][2][3] Company Overview - GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on immuno-oncology therapeutics utilizing its proprietary TriKE® NK cell engager platform [4] - The company has an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies based on TriKE® technology [4] Product Details - GTB-3650 is a second-generation TriKE that employs camelid nanobody technology to potentially enhance potency and binding affinity [3] - The Phase 1 trial will involve approximately 14 patients across seven cohorts, assessing safety, pharmacokinetics, pharmacodynamics, and clinical activity [3] - Dosing will occur in two-week cycles, with treatment periods lasting up to four months based on clinical benefit [3]